Bronchophyt

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT BRONCHOPHYT

Composition:

Active substances: 1 package (50 g) contains a mixture of herbal raw materials: calamus rhizomes (Calami radix) 4.5 g, marshmallow roots (Althaeae radix) 4.5 g, linden flowers (Tiliae flos) 4.5 g, marigold flowers (Calendulae flos) 4.5 g, licorice roots (Liquiritiae radix) 4.5 g, sage leaves (Salviae officinalis folium) 4.5 g, elder flowers (Sambuci flos) 4 g, nettle leaves (Urticae folium) 4 g, peppermint leaves (Menthae piperitae folium) 4 g, creeping thyme herb (Serpylli herba) 4 g, elecampane roots (Inulae helenii radix) 3.5 g, chamomile flowers (Matricariae flos) 3.5 g.

Pharmaceutical form. Herbal mixture.

Main physicochemical properties: a mixture of fragments of various shapes, grayish-green in color, with inclusions of orange and yellow of various shades. Odor is strong and pleasant.

Pharmacotherapeutic group. Agents used for cough and colds. Expectorants. ATC code R05C A.

Pharmacological Properties.

Pharmacodynamics.

The BRONCHOPHYTE preparation has secretolytic and secretokinetic effects. It stimulates serous cells of the bronchial mucosa glands, increasing the amount of mucous secretion, thereby altering the ratio of mucous and serous components of sputum. By increasing the volume of bronchial secretion and reducing its viscosity, expectoration of sputum is facilitated. BRONCHOPHYTE has anti-inflammatory and general strengthening properties.

Clinical characteristics.

Indications. Acute and chronic respiratory tract inflammatory diseases associated with cough and production of viscous sputum: acute and chronic bronchitis, bronchiectasis, pneumonia.

Contraindications. Acute and chronic renal failure, acute and chronic hepatic failure, liver cirrhosis, cholestatic disorders, hypokalemia, arterial hypertension of grade III, croup; hypersensitivity to any component of the medicinal product or to other plants of the Lamiaceae family, as well as known allergy to celery and birch pollen (cross-reactivity possible).

Special precautions. Should be used with caution in patients with increased blood coagulation, bronchial asthma, and spasmophilia.

Interaction with other medicinal products and other forms of interaction. The medicinal product should not be used concomitantly with cough-suppressant drugs due to the possible accumulation of sputum in the respiratory tract.

Prolonged concomitant use with cardiac glycosides, adrenocorticosteroids, antiarrhythmic agents (quinidine), laxatives, and thiazide and loop diuretics may lead to disturbances in water-electrolyte balance.

Special precautions for use

If symptoms persist or worsen during treatment within one week, or if dyspnea, fever, or purulent sputum appear, a physician should be consulted.

Use during pregnancy or breastfeeding. Due to insufficient experience with the use of the drug during pregnancy, it should be used during pregnancy only if prescribed by a physician and when the expected benefit to the mother outweighs the potential risk to fetal development. If use of the medicinal product is necessary, breastfeeding should be discontinued.

Ability to affect reaction speed when driving or operating machinery. Has no effect.

Dosage and Administration.

Steep 2 tablespoons of the mixture in 500 ml of boiling water; let stand, covered, for 1 hour and then strain.

For adults and children aged 7 years and older, take warm, ⅔ cup (150 ml) 20–30 minutes before meals, three times daily.

Duration of use should be determined by a physician. Typically, the treatment course lasts 3–4 weeks.

Children. The preparation is contraindicated in children under 7 years of age.

Overdose. Possible development of edema, dyspeptic symptoms, increased arterial pressure, and intensification of adverse reactions.

Side effects.

The medicinal product is generally well tolerated by patients. However, due to its multi-component composition, allergic reactions may occur, mostly in cases of individual hypersensitivity to any of the components or in case of violation of the recommended dosage regimen. These may include hyperemia, rashes, itching, skin swelling, contact dermatitis, urticaria; gastrointestinal disturbances (nausea, vomiting, diarrhea, etc.). If any adverse reactions occur, patients should consult a physician.

Shelf life. 2 years. Do not use after the expiry date stated on the packaging.

Storage conditions. In the original packaging, at a temperature not exceeding 25 °C, in a place inaccessible to children.

Packaging. 50 g per sachet, placed in a carton.

Prescription status. Over-the-counter.

Manufacturer. LLC "Scientific and Production Pharmaceutical Company "EYM".

Manufacturer's address and location of business activity. 20 lit. "A-5", Kharkivs'kykh Dyviziy Street, Kharkiv, Kharkiv region, 61091, Ukraine.

INSTRUCTIONS

for medical use of the medicinal product

BRONCHOPHYT

Composition:

Active ingredients: 1 package (100 g) contains a mixture of herbal raw materials: Calami radix (Acori rhizoma) 9 g, Althaeae radix (Althaea root) 9 g, Tiliae flos (Linden flowers) 9 g, Calendulae flos (Marigold flowers) 9 g, Liquiritiae radix (Licorice root) 9 g, Salviae officinalis folium (Sage leaf) 9 g, Sambuci flos (Elder flowers) 8 g, Urticae folium (Nettle leaf) 8 g, Menthae piperitae folium (Peppermint leaf) 8 g, Serpylli herba (Thyme herb) 8 g, Inulae helenii radix (Elecampane root) 7 g, Matricariae flos (Chamomile flowers) 7 g.

Pharmaceutical form. Herbal mixture.

Main physicochemical characteristics: a mixture of irregularly shaped fragments of grayish-green color with inclusions of orange and yellow hues of various shades. Odor is strong and pleasant.

Pharmacotherapeutic group. Medicinal products used for cough and colds. Expectorants. ATC code R05C A.

Pharmacological properties.

Pharmacodynamics.

The BRONHOFIT preparation has secretolytic and secretokinetic effects. It stimulates serous cells of the bronchial mucosa glands, increasing the amount of mucous secretion, thereby altering the ratio of mucous and serous components of sputum. Due to increased bronchial secretion and reduced viscosity, expectoration of sputum is facilitated. BRONHOFIT has anti-inflammatory and general strengthening properties.

Clinical characteristics.

Indications. Acute and chronic inflammatory diseases of the respiratory tract accompanied by cough with production of viscous sputum: acute and chronic bronchitis, bronchiectasis, pneumonia.

Contraindications. Acute and chronic renal failure, acute and chronic hepatic failure, liver cirrhosis, cholestatic disorders, hypokalemia, arterial hypertension of grade III, croup; hypersensitivity to any component of the medicinal product or to other plants of the Lamiaceae family, as well as known allergy to celery and birch pollen (possible cross-reaction).

Special precautions. Should be used with caution in patients with increased blood coagulability, bronchial asthma, and spasmophilia.

Interaction with other medicinal products and other forms of interaction. The preparation should not be used concomitantly with cough suppressants due to the possible accumulation of sputum in the respiratory tract.

Prolonged concomitant use with cardiac glycosides, adrenocorticosteroids, antiarrhythmic agents (quinidine), laxatives, and thiazide and loop diuretics may lead to disturbances in water-electrolyte balance.

Special precautions for use.

If symptoms persist or worsen during treatment within one week, or if dyspnea, elevated body temperature, or purulent sputum occur, consult a physician.

Use during pregnancy or breastfeeding. Due to insufficient experience with the use of the drug during pregnancy, it should be administered only on a physician's recommendation when the expected benefit to the mother outweighs the potential risk to fetal development. If it is necessary to use the medicinal product, breastfeeding should be discontinued.

Ability to affect reaction speed when driving or operating machinery. Has no effect.

Dosage and Administration.

Steep 2 tablespoons of the mixture in 500 ml of boiling water, let stand in a closed container for 1 hour, then strain.

For adults and children aged 7 years and older, take warm, ⅔ cup (150 ml) 20–30 minutes before meals, three times daily.

The duration of treatment is determined by a physician. Typically, the treatment course lasts 3–4 weeks.

Children. The preparation is contraindicated for children under 7 years of age.

Overdose. Possible development of edema, dyspeptic symptoms, increased arterial pressure, and intensification of adverse reactions.

Adverse reactions.

The medicinal product is generally well tolerated by patients. However, due to its multi-component composition, allergic reactions may occur, mostly in cases of individual hypersensitivity to any of the components or in violation of the recommended dosage regimen. These may include hyperemia, rashes, itching, skin swelling, contact dermatitis, urticaria; gastrointestinal disturbances (nausea, vomiting, diarrhea, etc.). In case of any adverse reactions, consult a physician.

Shelf life. 2 years. Do not use after the expiry date stated on the packaging.

Storage conditions. In the original packaging at a temperature not exceeding 25 °C, in a place inaccessible to children.

Packaging. 100 g per packet, placed in a carton.

Availability. Over-the-counter.

Manufacturer: LLC "Scientific and Production Pharmaceutical Company "EYM".

Manufacturer's location and address of business activity: Ukraine, 61091, Kharkiv region, Kharkiv, st. Kharkivskikh Diviziy, 20, lit. "A-5".

INSTRUCTION

for medical use of the medicinal product

BRONCHOPHYT

Composition:

Active substances: 1 filter bag (1.5 g) contains a mixture of herbal raw materials: Calamus rhizome (Calami radix) 135 mg, Marshmallow root (Althaeae radix) 135 mg, Lime flowers (Tiliae flos) 135 mg, Marigold flowers (Calendulae flos) 135 mg, Liquorice root (Liquiritiae radix) 135 mg, Sage leaf (Salviae officinalis folium) 135 mg, Elder flowers (Sambuci flos) 120 mg, Nettle leaf (Urticae folium) 120 mg, Peppermint leaf (Menthae piperitae folium) 120 mg, Thyme herb (Serpylli herba) 120 mg, Elecampane root (Inulae helenii radix) 105 mg, Chamomile flowers (Matricariae flos) 105 mg.

Pharmaceutical form. Herbal mixture.

Main physicochemical properties: a mixture of irregularly shaped fragments of greyish-green color with inclusions of orange and yellow of various shades. Odor strong, pleasant.

Pharmacotherapeutic group. Medicinal products used in cough and colds. Expectorants. ATC code R05C A.

Pharmacological Properties.

Pharmacodynamics.

The BRONCHOPHYTE preparation has secretolytic and secretokinetic effects. It stimulates the serous cells of the bronchial mucosa glands, increasing the amount of mucous secretion, thus altering the ratio between the mucous and serous components of sputum. By increasing the volume of bronchial secretion and reducing its viscosity, expectoration of sputum is facilitated. BRONCHOPHYTE possesses anti-inflammatory and general strengthening properties.

Clinical characteristics.

Indications. Acute and chronic inflammatory diseases of the respiratory tract accompanied by cough with production of viscous sputum: acute and chronic bronchitis, bronchiectasis, pneumonia.

Contraindications. Acute and chronic renal failure, acute and chronic hepatic failure, liver cirrhosis, cholestatic disorders, hypokalemia, arterial hypertension of grade III, croup; hypersensitivity to any component of the medicinal product or to other plants of the Lamiaceae family, as well as known allergy to celery and birch pollen (possible cross-reaction).

Special precautions. Should be used with caution in patients with increased blood coagulation, bronchial asthma, and spasmophilia.

Interaction with other medicinal products and other forms of interaction. The medicinal product should not be used concomitantly with cough suppressants due to the risk of sputum accumulation in the respiratory tract.

Prolonged concomitant use with cardiac glycosides, adrenocorticosteroids, antiarrhythmic agents (quinidine), laxatives, thiazide and loop diuretics may lead to disturbances in water-electrolyte balance.

Special precautions for use

If symptoms persist or worsen during one week of treatment, or if dyspnea, fever, or purulent sputum occur during therapy, a physician should be consulted.

Use during pregnancy or breastfeeding. Due to insufficient experience with the use of the medicinal product during pregnancy, it should be used during pregnancy only on the advice of a physician when the expected benefit to the mother outweighs the potential risk to fetal development. If it is necessary to use the medicinal product, breastfeeding should be discontinued.

Ability to affect reaction speed when driving or operating machinery. Has no effect.

Method of Administration and Dosage

Pour 150 ml of boiling water over 2 filter packets and let steep, covered, for 15 minutes.

For adults and children aged 7 years and older, take 150 ml of the warm preparation 20–30 minutes before meals, three times daily.

The duration of treatment should be determined by a physician. Typically, the treatment course lasts 3–4 weeks.

Children. The medication is contraindicated in children under 7 years of age.

Overdose. Overdose may result in edema, dyspeptic symptoms, increased arterial blood pressure, and intensification of adverse reactions.

Side effects.

The medicinal product is generally well tolerated by patients. However, due to its multi-component composition, allergic reactions may occur, mostly in cases of individual hypersensitivity to any of the components or when the recommended dosage regimen is not followed. Such reactions may include hyperemia, rashes, itching, skin swelling, contact dermatitis, urticaria; gastrointestinal disturbances (nausea, vomiting, diarrhea, etc.). If any adverse reactions occur, consult a physician.

Shelf life. 2 years. Do not use after the expiry date stated on the packaging.

Storage conditions. Store in the original packaging at a temperature not exceeding 25 °C, in a place inaccessible to children.

Packaging. 1.5 g in a filter bag, 20 bags per pack.

Availability. Over-the-counter.

Manufacturer. LLC "Scientific and Production Pharmaceutical Company "EYM".

Manufacturer's location and address of business activity. Ukraine, 61091, Kharkiv region, city of Kharkiv, St. Kharkivs'kykh Dyviziï, 20, lit. "A-5".